Molecular mechanisms of bortezomib resistant adenocarcinoma cells
about
Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome bindingTargeting neuroblastoma stem cells with retinoic acid and proteasome inhibitorA phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.The resistance mechanisms of proteasome inhibitor bortezomib.Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma ModelProteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy.Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma.Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasoneTargeting ubiquitination for cancer therapies.A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors.Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers.Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.Harnessing proteasome dynamics and allostery in drug design.Discovery of Therapeutic Deubiquitylase Effector Molecules: Current Perspectives.Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.SCF ubiquitin ligase-targeted therapies.Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.Molecular mechanisms of acquired proteasome inhibitor resistance.Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma.(Immuno)proteasomes as therapeutic target in acute leukemia.Positioning of proteasome inhibitors in therapy of solid malignancies.Unbiased compound-protein interface mapping and prediction of chemoresistance loci through forward genetics in haploid stem cells.Soluble and Cell-Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma.
P2860
Q27677425-1A0A56C4-1718-4474-9C8E-DFFA0B3D9C6AQ28534151-C5C172AD-897B-49DD-BE79-D8B0D0719673Q33416105-323AE298-3DD1-41A3-B540-55948C1EDF36Q34256126-E2C24C30-9AAD-4BC9-9F2F-A5B560020960Q34478543-D08FDD1B-4997-4F34-967E-D0CF64901D0EQ35408665-EC67B661-E675-49A9-A59D-8D3C047A1E9CQ36146344-8351C7D9-B744-4AAE-99F5-D3DE558CFC23Q37132862-01422520-7336-4212-9562-7D8AA39FC237Q37158445-196642F5-7DCB-43E9-AED9-E60B06D2A667Q37199819-EB6D3B36-6A90-4850-91E4-CB3664F8EC71Q37377911-AF2BD6D1-5C5C-4CDC-8B2E-63745529E5B9Q37590014-6EAB4929-3771-4312-A843-D3993CD595AEQ37688848-4F0DD4D8-98DC-4438-9598-1C54813F92CFQ38019864-1BDE70D6-B1E6-40C8-9B89-A2D271A7511CQ38177328-A4D100AF-34FA-406E-9700-1A0FA293111DQ38196269-A3233182-4568-446F-BCCF-A0ABFDDF2C2AQ38252591-B0840FFC-7F7A-44CC-A456-B0A670C4E957Q38267996-98BFF807-6A67-4077-B1F0-D38FB5CE83BFQ39034873-81835641-7602-44F8-852F-11E43341D79DQ39174431-02E8A781-8D92-4CFB-8060-6EF45CE1E073Q39278628-B73BA9B2-8DF8-48D2-8E13-E02F951C1F5AQ42532029-0F00114C-D680-4293-8162-F639B62CA17EQ47131929-11B4F6FE-4C5B-48E6-B40A-165C66A0C8C4Q47353792-89959DAC-E996-4668-A028-E8C3A9218903Q50417403-98D04503-5381-41CA-BA8D-C1117422ECBCQ55091606-C5B67B08-CE9F-4566-A110-2B4022DC2441
P2860
Molecular mechanisms of bortezomib resistant adenocarcinoma cells
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Molecular mechanisms of bortezomib resistant adenocarcinoma cells
@ast
Molecular mechanisms of bortezomib resistant adenocarcinoma cells
@en
Molecular mechanisms of bortezomib resistant adenocarcinoma cells
@nl
type
label
Molecular mechanisms of bortezomib resistant adenocarcinoma cells
@ast
Molecular mechanisms of bortezomib resistant adenocarcinoma cells
@en
Molecular mechanisms of bortezomib resistant adenocarcinoma cells
@nl
prefLabel
Molecular mechanisms of bortezomib resistant adenocarcinoma cells
@ast
Molecular mechanisms of bortezomib resistant adenocarcinoma cells
@en
Molecular mechanisms of bortezomib resistant adenocarcinoma cells
@nl
P2093
P2860
P1433
P1476
Molecular mechanisms of bortezomib resistant adenocarcinoma cells
@en
P2093
Christopher J Kirk
Erika Suzuki
Jonathan Keats
Mark K Bennett
P Leif Bergsagel
Shirin Arastu-Kapur
Susan Demo
P2860
P304
P356
10.1371/JOURNAL.PONE.0027996
P407
P577
2011-01-01T00:00:00Z